OPK vs. BCRX, LGND, FOLD, CLDX, MNKD, INVA, DVAX, NVAX, GERN, and RGLS
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
OPKO Health vs.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
OPKO Health has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 2 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.71 beat BioCryst Pharmaceuticals' score of 0.91 indicating that OPKO Health is being referred to more favorably in the news media.
OPKO Health has a net margin of -18.65% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat OPKO Health's return on equity.
OPKO Health received 14 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. However, 67.16% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.60% of users gave OPKO Health an outperform vote.
BioCryst Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
BioCryst Pharmaceuticals presently has a consensus target price of $16.56, indicating a potential upside of 50.37%. OPKO Health has a consensus target price of $2.75, indicating a potential upside of 99.28%. Given OPKO Health's higher probable upside, analysts clearly believe OPKO Health is more favorable than BioCryst Pharmaceuticals.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
OPKO Health beats BioCryst Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
This page (NASDAQ:OPK) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy OPK Stock Free OPK Stock Alerts